'$900 For Mere Fitness Tracker?': The Liver Doc Hits Back As Deepinder Goyal Defends 'Temple' Device, Calls It 'Science Fraud'

Zomato founder Deepinder Goyal has strongly defended the company's fitness tracker, Temple, amid criticism from medical professionals who claim it lacks scientific validity. Goyal dismissed these concerns as 'science fraud,' arguing that the device is a legitimate health tool. This public dispute highlights the growing scrutiny over consumer wearables and their accuracy in tracking health metrics.
For investors, this incident underscores the reputational risks associated with consumer hardware ventures. While the broader market is not directly affected, the controversy could impact Zomato's brand image and consumer trust. Investors should monitor how the company manages this PR challenge and whether it clarifies the device's data accuracy to reassure users.
Key takeaways
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
Why it matters
A routine update. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.












